ICAM1 and osteoarthritis: The downstream benefits were as follows: decreased low grade inflammation—as indicated by decreased ICAM1 expression and decreased RAGE at the protein level [1]; decreased ECM remodeling by decreased expression of MMP13—a key factor in ECM proteolysis in the progression of osteoarthritis [52]; and decreased biomarkers of cellular senescence—temporary decreases in GLB1 and SERPINB2 [46,47].